Zhenkua Didu Powder Veterinary Grade API is supplied as a powder-form active pharmaceutical ingredient for pharmaceutical manufacture of veterinary finished dose forms. Model identification is by the trade name “Zhenkua Didu Powder” and the grade qualifier “veterinary grade API”; no separate numerical model code appears in public documentation. The powder is designated for use as a starting material in tablets, injections, capsules, powders, granules, premixes, and solutions. It is not intended for direct administration and should be handled only in licensed manufacturing facilities. Because published data for this specific configuration is limited, batch release decisions are based on the producer’s certificate of analysis. That certificate should address identification, assay, related substances, residual solvents, loss on drying, residue on ignition, heavy metals, microbial enumeration, and, where injectable manufacturing is intended, bacterial endotoxins. The exact numerical limits are product-specific and must be obtained from the registered veterinary product dossier.

What Manufacturing Routes Require Release Data Beyond Basic Assay?

Solid oral dosage forms such as tablets and capsules require particle size distribution, bulk density, tapped density, and powder flow data because these characteristics control die fill consistency, weight variation, and content uniformity. Injectable solutions impose a different release burden: bacterial endotoxins, particulate matter, solution clarity, pH, and sterility risk become dominant. Premix and granule formulations add carrier blend homogeneity and segregation tendency. The API certificate of analysis cannot therefore be generic; the required test panel must be aligned with the dosage form route. For tablets and capsules, USP <616> and USP <1174> methods for density and powder flow are commonly referenced. For injections, USP <85> and USP <788> apply to endotoxin and particulate matter. Published data for this specific product’s performance under each route is limited, so formulators should commission route-specific preformulation studies.

In production-scale solid dosage manufacturing, the powder is generally discharged into a clean, humidity-controlled dispensing area before being passed through a sieve or conical mill. The objective is to break soft agglomerates without imparting excessive fines. A 500 µm or 800 µm mesh may be used as a guard screen depending on the target granulation, but the exact aperture should be selected from particle size data. If the API is cohesive, blending with a low-hygroscopic filler in a tumble blender at speeds below 15 rpm reduces segregation risk. Direct compression formulations may require a glidant such as colloidal silicon dioxide at 0.1–0.5 wt% to improve flow; however, the necessary concentration must be verified by Carr index and Hausner ratio measurements rather than assumed. High-shear granulation is often preferred when the API dose is low and content uniformity is critical, because binder solution distribution is more controlled than dry blending. If a 600 L bin blender is used, the fill level should be kept between 30% and 70% of working volume to avoid dead zones or insufficient shear.

When the API Is Formulated into Injectable Solutions, Endotoxin and Particulate Control Supersede Conventional Powder Flow Tests

Injectable product development shifts the critical quality attribute profile from powder flow to solubility, clarity, pH, bacterial endotoxin, and subvisible particulate burden. The powder may be dissolved in Water for Injection under controlled pH and temperature, then filtered through a 0.22 µm membrane. Filter selection must account for possible adsorption of the active substance onto polyvinylidene fluoride or polyethersulfone membranes. Terminal sterilization by autoclaving at 121 °C for 15 min may be evaluated only if solution stability data demonstrate acceptable degradation; otherwise aseptic filtration is required. The release specification should include bacterial endotoxin limits based on the maximum endotoxin dose for the target species, not merely a default pharmacopoeial threshold. Particulate matter in the final solution should comply with the limits in USP <788> or Ph. Eur. 2.9.19. Because published data for this specific configuration is limited, lyophilization compatibility and light exposure stability must be determined experimentally.

Particle Size Distribution, Bulk Density, and Flow in Tablet and Capsule Manufacturing

Tablet and capsule manufacture requires that the API particle size distribution be controlled relative to the excipient particle size. If the API is micronized to a D90 below 10 µm, agglomeration may increase electrostatic attraction and reduce flow; over-lubrication with magnesium stearate may then delay disintegration. If the API is coarse, dissolution and content uniformity may become limiting. The optimal particle size is route-dependent and should be established through factorial studies that measure blend homogeneity, tablet hardness, friability, disintegration, and dissolution. Bulk density and tapped density are used to calculate the Carr index and Hausner ratio; flowable powders typically show a Carr index below 15, but this product’s measured value must be confirmed from the lot certificate. Capsule filling on automatic machines is sensitive to bulk density variation, so hopper loading and humidity control below 50% RH may be necessary. High-shear granulator impeller speeds from 200 rpm to 500 rpm and chopper speeds from 1000 rpm to 3000 rpm are typical starting ranges; the endpoint should be determined by power consumption rise and granule size rather than fixed time.

When the API represents less than 1 wt% of the finished tablet blend, ordered mixing may be necessary. The API should first be mixed with a portion of the filler or a compatible carrier in a smaller high-shear mixer before being transferred to the main blender. Sampling thieves can introduce systematic errors if the probe tip disturbs the bed; therefore, blend uniformity should be confirmed by unit dose sampling in the finished tablet or capsule rather than by thief sampling alone. Segregation during compression occurs when coarse excipient particles reorder under machine vibration. A force feeder with rotating paddle wheels is commonly used to maintain die fill; if the powder flow is insufficient, weight variation may exceed 2% relative standard deviation. Published data for this specific API under low-dose dry blending is limited, so laboratory-scale studies should be used to define the mixing order and time.

Premix manufacturing typically involves stepwise geometric dilution of the API into a carrier such as lactose monohydrate, corn starch, or calcium carbonate. The final premix should be assayed for blend uniformity using a sampling plan that represents at least 10 sampling points across the batch. If the coefficient of variation exceeds 5%, segregation may be occurring during transfer or sifting. Granule formulations may be produced by wet granulation followed by fluid-bed drying with inlet air temperature between 50 °C and 70 °C, provided thermal degradation data support that range. The moisture content after drying should be monitored by loss on drying because residual moisture above 3% may promote caking or microbial growth. For this API, published stability data for these specific manufacturing conditions is limited; therefore, process validation batches are required.

Micronization may be required for injection or solution formulations but can introduce amorphous content on the particle surface. The amorphous fraction may absorb moisture and alter dissolution. If a fluid energy mill is used, the grinding pressure, feed rate, and classifier speed should be recorded because they influence the D10, D50, and D90 values. Milling should be followed by an equilibration period in a controlled environment to allow surface relaxation before packaging. If the API is sensitive to shear-induced degradation, cryogenic milling or wet milling with a subsequent drying step may be preferred. The resulting particle size distribution should be measured by laser diffraction rather than sieve analysis when the target D90 is below 20 µm. Published data for this specific product after micronization is limited.

Across Solid, Premix, and Injectable Routes, Release Testing Must Be Route-Specific

The table below lists quality attributes that are commonly required for a veterinary-grade API intended for multiple dosage form routes. Acceptance criteria are not included because they are product-specific and should be drawn from the approved veterinary medicinal product dossier or the manufacturer’s certificate of analysis.

Compared with feed-grade or technical-grade powders, the veterinary API grade is expected to be controlled under pharmacopoeial test methods and supported by batch release documentation. Feed additive powders may be released on macroscopic appearance and active content alone without bacterial endotoxin testing or related substance profiling. A premix or formulated powder already contains carriers and is not equivalent to the pure API, because the formulator loses the ability to control tablet compression or injection tonicity independently. This product is therefore suited to manufacturers that require a clean, single-entity starting material for multiple finished dose forms, provided the absence of excipients is confirmed by the certificate of analysis. For injectable use, the risk of excipient interference is eliminated, but the formulator assumes responsibility for pH adjustment, isotonicity, sterility, and container-closure compatibility.

The Release Specification, Not the Active Moiety, Defines the API Grade

The distinction lies in the release specification, not necessarily in the active moiety. Veterinary API grade material should be manufactured under veterinary Good Manufacturing Practice and supported by a complete certificate of analysis that includes residual solvents, related substances, heavy metals, and microbial limits. Technical-grade material may contain process-related impurities at higher levels and may not be tested for bacterial endotoxins. Feed-grade powder may be diluted on carriers and may not meet the assay limit required for pharmaceutical compounding. For tablet and capsule applications, the API grade should provide a controlled particle size distribution, reducing the need for additional milling and lowering batch-to-batch weight variation. For injectable solutions, the API grade is expected to meet low endotoxin specifications, but the actual limit must be calculated from the intended dose and target species.

Controlling Moisture Uptake in Multi-Route API Storage

Stability of the powder during storage is influenced by moisture ingress, oxygen exposure, and light. The container closure system should be selected after sorption isotherms are generated by dynamic vapour sorption. If the powder is hygroscopic, handling in an isolator with relative humidity below 30% may be required. Bulk storage in sealed polyethylene bags inside fibre drums is common for veterinary APIs, but the actual packaging must be confirmed on the certificate of analysis. Temperature excursions during transport should be evaluated against the manufacturer’s stated storage range. For multi-route use, retain samples should be tested for appearance, assay, and moisture at predetermined intervals. Because published data for this specific product’s long-term stability is limited, the manufacturer’s stability commitment and retest date should govern inventory use.

Analytical method transfer should include forced degradation samples to confirm specificity. Related substances methods are typically high-performance liquid chromatography with ultraviolet detection; for low-level impurities, a single-point external standard may be acceptable but peak purity verification is required. Assay of the powder before and after aqueous dissolution should be used to establish mass balance. If the chromatographic profile shows unresolved peaks at the void volume, ion-pair or hydrophilic interaction conditions may be required. Because the product is intended for multiple routes, the same validated method should be applied across all finished dose forms unless matrix interference is demonstrated.

For solution formulations, the API is usually dissolved in a buffered vehicle before adjustment of pH and tonicity. The clarity of the resulting solution may be influenced by residual particulates, undissolved polymorphic forms, or degradation products. Packaging selection should consider light exposure and oxygen permeability; amber glass vials or multilayer plastic containers may be required if photodegradation data indicate sensitivity. The product should be stored in tightly closed packaging at a temperature specified by the manufacturer, and desiccant use should be evaluated when the ambient relative humidity exceeds 60%. Solution pH can influence chemical stability and tissue tolerance. Buffering agents such as citric acid/phosphate buffers may be used if the API remains soluble in the selected pH range. The final solution should be protected from headspace oxygen by nitrogen sparging when oxidative degradation is suspected. If the API exhibits low solubility, solubilizers such as propylene glycol or polyethylene glycol may be evaluated, but only after verifying the safety of the co-solvent for the target species. The final formulation should be assessed for subvisible particles after freeze-thaw cycling if cold storage is planned. Published data for this specific product in co-solvent systems is limited.